Compare GSK plc (GSK) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares MSCI China ETF — how do they compare? GSK plc trades at $52.8 (market cap $101.34B), while iShares MSCI China ETF trades at $54.15. The key difference: GSK plc pays a 3.49% dividend while iShares MSCI China ETF pays none, and GSK plc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| GSK | MCHI | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $66.99 |
52-Week Low | $36.20 | $50.48 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
MCHI trades at $54.10, up 1.63% with a bullish technical signal from moving averages. The stock shows strong momentum with ADX indicating a strong trend, though RSI levels suggest potential overbought conditions. Recent news highlights China's AI and manufacturing resurgence, with exports growing 19.4% year-over-year in May 2026 (Reuters, 2026-06-08).
The outlook remains cautiously optimistic given China's $295 billion AI investment plan (Bloomberg, 2026-06-09) and factory rebound. However, risks include US-China trade tensions and concerns about Chinese equities being value traps. Analyst sentiment is mixed with some maintaining sell ratings due to structural headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
